13F Holdings
中文EN

CCEL CRYO CELL INTERNATIONAL INC

Services-Misc Health & Allied Services, NEC · NYSE · SEC CIK 862692 · Fiscal year ends 11/30

Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.0%
TTM net income YoY-310.8%
TTM EPS YoY-380.0%
Revenue 3-yr CAGR-0.1%
Net income 3-yr CAGR—

Margins

Gross margin78.5%
Operating margin0.6%
Net margin-6.2%
FCF margin14.9%
EBITDA margin3.4%

Returns

ROE—
ROA-3.1%
ROIC (approx.)—
Asset turnover0.50x

Leverage & solvency

Liabilities / assets126.3%
Debt / equity—
Current ratio0.86x
Interest coverage0.10x

Cash quality & payout

Operating cash flow / net income-2.53x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-11-30FY20242024-11-30FY20232023-11-30FY20222022-11-30FY20212021-11-30
Income statement
Revenue$31.57M$31.99M$31.34M$30.34M$28.88M
Cost of revenue$7.38M$7.95M$8.39M$8.79M$8.99M
Gross profit$24.19M$24.04M$22.95M$21.54M$19.90M
R&D expense$376,263$1.24M$1.17M$384,789$49,870
SG&A expense$18.22M$18.52M$17.17M$15.58M$14.61M
Operating income$482,394$3.48M-$12.30M$4.02M$4.02M
Interest expense$2.07M$1.86M$1.24M$1.52M$1.38M
Pretax income-$2.34M$2.80M-$13.36M$3.32M$2.61M
Income tax$92,232$2.40M-$3.84M$547,540$527,710
Net income-$2.43M$402,095-$9.52M$2.77M$2.08M
EBITDA$1.47M$4.17M-$10.90M$5.52M$5.06M
EPS (basic)-0.300.05-1.140.330.26
EPS (diluted)-0.300.05-1.140.330.25
Dividends declared per share—0.25—0.90—
Weighted avg. shares (diluted)8.07M8.21M8.34M8.48M8.36M
Balance sheet
Cash & equivalents$319,031$560,960$406,067$1.70M$8.26M
Short-term investments$2.98M$2.94M$574,183$17,620$75,412
Receivables$6.85M$7.31M$6.58M$6.04M$5.25M
Inventory$408,794$657,703$768,877$851,230$921,213
Current assets$11.76M$12.55M$9.45M$9.61M$15.78M
PP&E, net$21.03M$21.89M$21.00M$13.60M$3.23M
Goodwill$1.94M$1.94M$1.94M$1.94M$1.94M
Intangibles$863,074$921,254$989,121$1.46M$1.56M
Total assets$61.73M$64.68M$64.68M$64.89M$60.66M
Current liabilities$19.79M$21.60M$20.86M$19.48M$21.07M
Long-term debt$8.35M$8.48M$8.60M$8.73M$1.90M
Total debt$8.35M$8.48M$8.60M$8.73M$1.90M
Total liabilities$80.33M$77.89M$72.25M$66.41M$56.48M
Shareholders' equity-$18.61M-$13.22M-$11.03M-$1.52M$4.18M
Net debt$8.03M$7.92M$8.19M$7.03M-$6.37M
Shares outstanding8.06M8.08M8.29M8.50M8.55M
Cash flow statement
Operating cash flow$5.48M$6.01M$8.92M$8.57M$7.93M
Capital expenditure$230,475$2.40M$6.84M$12.17M$1.83M
Free cash flow$5.25M$3.61M$2.08M-$3.60M$6.09M
Investing cash flow-$975,332-$4.88M-$8.14M-$15.28M-$6.95M
Financing cash flow-$4.75M-$979,118-$2.07M$147,862-$3.07M
Depreciation & amortization$985,242$693,847$1.40M$1.50M$1.04M
Stock-based compensation$417,101$781,128$816,639$461,345$301,616
Dividends paid$3.23M$2.02M$0$7.67M$0
Share buybacks$169,502$1.42M$799,036$1.82M$249,377

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.